Loading stock data…
MESO
$14.28+0.48 (+3.48%)
After Hours$14.28+0.00 (+0.00%)· Last close Jun 9
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Mesoblast Limited in the Healthcare sector is trading at $14.28. Wall Street consensus targets $35.00 (2 analysts), implying a +145.1% move over the next 12 months. The stock is currently 34% below its 52-week high of $21.50, remaining 12.2% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +145.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$14.28
Potential Downside
0%
Whystock Fair Value$14.28
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Mean target$35.00+145.1%
Range$35.00 – $35.00
Fundamentals
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-14.25%
Volume
Today's trading volume
173,561
Recent News
ASX Growth Companies With High Insider Ownership
As Australian shares rebound from a significant market downturn, driven by global events and domestic fiscal policies, investors are keenly observing the landscape for opportunities. In this environment, growth companies with high insider ownership can be particularly appealing due to their potential for alignment of interests between management and shareholders.
ASX Penny Stocks With Market Caps Under A$3B To Consider
Australian shares are poised for a slight retreat, influenced by Wall Street's recent cooling and ongoing global economic discussions. Despite the fluctuating market conditions, penny stocks—often overlooked due to their smaller size or newer status—can still present valuable opportunities when backed by solid financials. In this article, we explore several promising Australian penny stocks that combine financial strength with potential for long-term growth.
ASX Stocks Trading At An Estimated Discount Of Up To 45.8% Below Intrinsic Value
The Australian share market is experiencing a downturn, influenced by the recent budget announcement and external pressures such as rising U.S. inflation, which has caused some uncertainty among investors. In this environment, identifying undervalued stocks can be an effective strategy for investors looking to capitalize on potential discounts relative to intrinsic value.
How Completion Of RMAT Phase 3 Enrollment At Mesoblast (ASX:MSB) Has Changed Its Investment Story
Mesoblast Limited recently announced it has completed patient recruitment for its pivotal Phase 3 trial of rexlemestrocel-L in chronic low back pain due to degenerative disc disease, a placebo-controlled study following at least 300 patients for 12 months. This milestone moves the program closer to potential FDA filing for rexlemestrocel-L, which holds RMAT designation in a multi-million patient indication closely linked to prescription opioid use. We’ll now examine how reaching full...
ASX Penny Stocks To Watch In April 2026
As the Australian market faces its seventh consecutive day in the red, with inflation expected to spike to nearly three-year highs, investor sentiment has turned bearish. Despite these challenging conditions, penny stocks remain a relevant investment area for those seeking growth opportunities in smaller or newer companies. While the term 'penny stock' might seem outdated, these stocks can offer significant potential when backed by strong financials, and we've identified three such examples...